Quick, everyone sell ALL of your shares IMMEDIATELY!!! R&D focused Biotech company doing more R&D than before, spending more on R&D than before...
NEU Neuren Pharmaceuticals dips after pediatric Angelman Syndrome Phase 2 trial results fail to impress
Week 32 Wrap: AI is clearly overhyped – but did we see ‘bubble’ burst already? Plus RBA decision; Japan’s wild week & Google ruling